Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-10-07. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: radiationheartcancerchronicregion
  Phrases that lowered it: patientsbased onparticipantslesionsmg
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 17.7% (lowers risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 3 (raises risk) · Sponsor's track record
• Sponsor's past trials: 6 (raises risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 8960 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drugs with FDA adverse-event history: 8 (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports before start: 47873 (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Disease area, dermatology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer NCT00721513 · started 2008 · scored riskier than 89% of active trials completed
• Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer NCT01326923 · started 2010 · scored riskier than 98% of active trials terminated
• Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer NCT00820248 · started 2008 · scored riskier than 97% of active trials completed
• Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer NCT00833261 · started 2008 · scored riskier than 92% of active trials completed
• InductionChemo-Radio-Antibody-Treatment NCT01181401 · started 2010 · scored riskier than 48% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.